View in EDS

Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model

Saved in:
Bibliographic Details
Title: Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model
Authors: Verreault, M.1 mverreau@bccrc.ca, Strutt, D.1, Masin, D.1, Anantha, M.1, Waterhouse, D.1, Yapp, D.T.1,2, Bally, M.B.1,2,3,4 mbally@bccrc.ca
Source: Journal of Controlled Release. Feb2012, Vol. 158 Issue 1, p34-43. 10p.
Subjects: Nanoparticles, Lipids, Glioblastoma multiforme, Intravenous therapy, Drug efficacy, Cell proliferation
Abstract: Abstract: Given compelling evidences supporting the therapeutic potential of irinotecan (IRN) for patients with glioblastoma (GBM), the present study evaluated the activity of Irinophore C™ (IrC™), a lipid-based nanopharmaceutical formulation of IRN, in GBM. The levels of IRN and SN-38 were determined in plasma and brain after a single intravenous dose of IRN or IrC™ in tumor-free mice. Treatment with IrC™ significantly increased the plasma AUC0–24h of the active (lactone) forms of IRN and SN-38 when compared to free drug (760 and 30-fold increase, respectively). Levels of IRN and SN-38 in brain tissue were also increased significantly (compared to IRN treatment) following IrC™ administration. A tolerability study revealed that IrC™ is better tolerated than IRN. The efficacy of IrC™ and IRN was assessed in an orthotopic model of GBM. The therapeutic efficacy of IrC™ given at 25mg/kg weekly was comparable to the efficacy achieved using twice the dose of IRN. At the maximum tolerated dose, IrC™ (100mg/kg) increased the survival time of tumor-bearing mice of 83% compared to untreated animals. Ki67 immunostaining analysis of IrC™-treated tumors revealed a transient increase in cell proliferation after treatment. The results justify further studies evaluating the use of IrC™ for treating GBM. [Copyright &y& Elsevier]
Copyright of Journal of Controlled Release is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
FullText Text:
  Availability: 0
Header DbId: egs
DbLabel: Engineering Source
An: 73278531
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Verreault%2C+M%2E%22">Verreault, M.</searchLink><relatesTo>1</relatesTo><i> mverreau@bccrc.ca</i><br /><searchLink fieldCode="AR" term="%22Strutt%2C+D%2E%22">Strutt, D.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Masin%2C+D%2E%22">Masin, D.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Anantha%2C+M%2E%22">Anantha, M.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Waterhouse%2C+D%2E%22">Waterhouse, D.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Yapp%2C+D%2ET%2E%22">Yapp, D.T.</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Bally%2C+M%2EB%2E%22">Bally, M.B.</searchLink><relatesTo>1,2,3,4</relatesTo><i> mbally@bccrc.ca</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Journal+of+Controlled+Release%22">Journal of Controlled Release</searchLink>. Feb2012, Vol. 158 Issue 1, p34-43. 10p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Nanoparticles%22">Nanoparticles</searchLink><br /><searchLink fieldCode="DE" term="%22Lipids%22">Lipids</searchLink><br /><searchLink fieldCode="DE" term="%22Glioblastoma+multiforme%22">Glioblastoma multiforme</searchLink><br /><searchLink fieldCode="DE" term="%22Intravenous+therapy%22">Intravenous therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+efficacy%22">Drug efficacy</searchLink><br /><searchLink fieldCode="DE" term="%22Cell+proliferation%22">Cell proliferation</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Abstract: Given compelling evidences supporting the therapeutic potential of irinotecan (IRN) for patients with glioblastoma (GBM), the present study evaluated the activity of Irinophore C™ (IrC™), a lipid-based nanopharmaceutical formulation of IRN, in GBM. The levels of IRN and SN-38 were determined in plasma and brain after a single intravenous dose of IRN or IrC™ in tumor-free mice. Treatment with IrC™ significantly increased the plasma AUC0–24h of the active (lactone) forms of IRN and SN-38 when compared to free drug (760 and 30-fold increase, respectively). Levels of IRN and SN-38 in brain tissue were also increased significantly (compared to IRN treatment) following IrC™ administration. A tolerability study revealed that IrC™ is better tolerated than IRN. The efficacy of IrC™ and IRN was assessed in an orthotopic model of GBM. The therapeutic efficacy of IrC™ given at 25mg/kg weekly was comparable to the efficacy achieved using twice the dose of IRN. At the maximum tolerated dose, IrC™ (100mg/kg) increased the survival time of tumor-bearing mice of 83% compared to untreated animals. Ki67 immunostaining analysis of IrC™-treated tumors revealed a transient increase in cell proliferation after treatment. The results justify further studies evaluating the use of IrC™ for treating GBM. [Copyright &y& Elsevier]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Journal of Controlled Release is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=73278531
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jconrel.2011.09.095
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 34
    Subjects:
      – SubjectFull: Nanoparticles
        Type: general
      – SubjectFull: Lipids
        Type: general
      – SubjectFull: Glioblastoma multiforme
        Type: general
      – SubjectFull: Intravenous therapy
        Type: general
      – SubjectFull: Drug efficacy
        Type: general
      – SubjectFull: Cell proliferation
        Type: general
    Titles:
      – TitleFull: Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Verreault, M.
      – PersonEntity:
          Name:
            NameFull: Strutt, D.
      – PersonEntity:
          Name:
            NameFull: Masin, D.
      – PersonEntity:
          Name:
            NameFull: Anantha, M.
      – PersonEntity:
          Name:
            NameFull: Waterhouse, D.
      – PersonEntity:
          Name:
            NameFull: Yapp, D.T.
      – PersonEntity:
          Name:
            NameFull: Bally, M.B.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 02
              Text: Feb2012
              Type: published
              Y: 2012
          Identifiers:
            – Type: issn-print
              Value: 01683659
          Numbering:
            – Type: volume
              Value: 158
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal of Controlled Release
              Type: main
ResultId 1